白蛋白结合型紫杉醇治疗晚期宫颈癌的疗效与安全性探讨

Efficacy and safety of albumin bound paclitaxel in patients with advanced cervical cancer

目的探讨白蛋白结合型紫杉醇对晚期宫颈癌患者的临床疗效及安全性，为临床治疗提供参考。方法选择武汉科技大学附属天佑医院收治的晚期宫颈癌患者47例为观察对象，收治时间为2015年5月～2017年1月，采用电脑随机分组方式将其分成对照组与实验组，对照组23例晚期宫颈癌患者实施紫杉醇化疗治疗，实验组24例晚期宫颈癌患者实施白蛋白结合型紫杉醇化疗治疗，观察2组晚期宫颈癌患者治疗后瘤体最大直径、症状缓解时间、生活质量评分、近期疗效、不良反应发生率等差异。结果2组晚期宫颈癌患者在治疗后各项观察指标均存在显著差异，具有统计学意义（P＜0.05），其中实验组近期疗效比对照组近期疗效高出31.52%。结论针对晚期宫颈癌患者实施白蛋白结合型紫杉醇化疗治疗能有效提高患者治疗的疗效，安全性较高，值得临床推广应用。

Objective To investigate the clinical efficacy and safety of albumin bound paclitaxel in patients with advanced cervical cancer,andto provide reference for clinical practice.Methods The hospital treated47cases of advanced cervical cancer patients as the observation object,fromMay2015to January2017,the computer randomly divided into the control group and the experimental group by computer,the control group of23cases of advanced cervical cancer patients from time with paclitaxel chemotherapy,24cases of advanced cervical cancer patients were treated withalbumin bound paclitaxel chemotherapy,observed patients with advanced cervical cancer after treatment of the two groups the maximum diameterof the tumor,relieve symptoms,efficacy,quality of life score,the incidence of adverse reactions were compared.Results The two groups of patientswith advanced cervical cancer after treatment,there are significant differences in the observation index,statistical significance(P<0.05),in whichthe short-term efficacy of the experimental group is higher than the short-term efficacy of the control group by31.52%.Conclusion For patients withadvanced cervical cancer,the implementation of albumin binding paclitaxel chemotherapy can effectively improve the efficacy of the treatment ofpatients,high safety,worthy of clinical treatment.